Biofrontera Inc.

BFRI

US09077D2099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.59 ^USD	-5.92%		-5.92%	-42.60%

Mar. 18	Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024
Mar. 15	Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 15, 2024 at 05:20 pm EDT

Biofrontera Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 0.013 million compared to USD 0.07 million a year ago. Revenue was USD 10.6 million compared to USD 10.14 million a year ago.

Net income was USD 3.53 million compared to net loss of USD 2.79 million a year ago. Basic earnings per share from continuing operations was USD 1.65 compared to basic loss per share from continuing operations of USD 2.13 a year ago.

Latest news about Biofrontera Inc.

Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024	Mar. 18
Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 15	CI
Biofrontera Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	Mar. 11	MT
Medicus Pharma Names COO	Mar. 05	MT
Biofrontera Inc. announced that it has received $8 million in funding	Feb. 21	CI
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera Ag	Feb. 20	CI
Biofrontera Inc. announced that it expects to receive $8 million in funding	Feb. 18	CI
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use	Feb. 05	CI
Certain Warrants of Biofrontera Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	Jan. 31	CI
Certain Common Stock of Biofrontera Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	Jan. 31	CI
Certain Stock options of Biofrontera Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	Jan. 31	CI
Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 11	CI
Biofrontera Inc. Terminates MidCap Business Credit Loan Agreement	Jan. 09	CI
Transcript : Biofrontera Inc., Q3 2023 Earnings Call, Nov 10, 2023	Nov. 10
Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023	Nov. 09	CI
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	Nov. 09	MT
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	23-10-10	MT
Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)	23-10-10	CI
Biofrontera Inc. Provides Revenue Guidance for the Third Quarter and Nine Months of 2023 and Re-Affirms Revenue Guidance for the Year 2023	23-10-04	CI
Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit	23-10-03	DJ
Biofrontera Inc. Appoints Samantha Widdicombe as Senior Director, Strategic Accounts and Communications	23-08-29	CI
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	23-08-28	MT
Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)	23-08-28	CI

Chart Biofrontera Inc.

Duration

Period

More charts

Company Profile

Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Biofrontera Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.59 USD

Average target price

16 USD

Spread / Average Target

+906.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BIOFRONTERA INC.	-42.60%	8.09M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Biofrontera Inc.

Equities

BFRI

US09077D2099

Pharmaceuticals

Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

EPS Revisions